KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Operating Expenses (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Operating Expenses for 15 consecutive years, with $162.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 19.62% year-over-year to $162.1 million, compared with a TTM value of $553.6 million through Dec 2025, down 0.62%, and an annual FY2025 reading of $553.6 million, down 0.62% over the prior year.
  • Operating Expenses was $162.1 million for Q4 2025 at Travere Therapeutics, up from $139.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $180.6 million in Q1 2024 and bottomed at $46.4 million in Q4 2021.
  • Average Operating Expenses over 5 years is $118.1 million, with a median of $123.1 million recorded in 2024.
  • The sharpest move saw Operating Expenses tumbled 72.6% in 2021, then soared 89.75% in 2023.
  • Year by year, Operating Expenses stood at $46.4 million in 2021, then surged by 58.05% to $73.4 million in 2022, then soared by 89.75% to $139.3 million in 2023, then fell by 2.71% to $135.5 million in 2024, then rose by 19.62% to $162.1 million in 2025.
  • Business Quant data shows Operating Expenses for TVTX at $162.1 million in Q4 2025, $139.9 million in Q3 2025, and $127.1 million in Q2 2025.